Pembrolizumab shows promise for some advanced, hard-to-treat rare cancers
MedicalXpress,
A study conducted by researchers at The University of Texas MD Anderson Cancer Center demonstrated acceptable toxicity and anti-t…
A study conducted by researchers at The University of Texas MD Anderson Cancer Center demonstrated acceptable toxicity and anti-t…
A study conducted by researchers at The University of Texas MD Anderson Cancer Center demonstrated acceptable toxicity and anti-t…
Oncology/Hematology > Other Cancers No disease progression at 27 weeks in almost 30% of patients with limited treatment options…
A study conducted by researchers at The University of Texas MD Anderson Cancer Center demonstrated acceptable toxicity and anti-t…